OpenNeedle Ask your own

Question explored with the scientific record

Answered on this page ↓

Is the shingles vaccine important for a 78 yo WM with an aortic graft?

Nov 20, 2026 · 5 sources used · OpenNeedle synthesis
The short version: shingles is a real risk for a 78-year-old, and the recombinant vaccine cuts it sharply, but no study here tested anyone with an aortic graft, and the safety data is short-term.

The benefit is the clearest of any vaccine in this thread. In the ZOE-70 trial of adults 70 and older, two doses of Shingrix cut shingles by about 90% versus placebo [3][4]. In the pooled trials it cut postherpetic neuralgia, the lingering nerve pain, by about 91% [3]. Real-world Medicare data put two-dose effectiveness lower, around 70% [2]. Protection fades slowly: about 84% still at year 8 [2].

The safety picture is thinner than the efficacy picture. The trials were funded by GlaxoSmithKline [3]. The main safety finding is reactogenicity: about 79% had injection-site pain versus 11% on placebo, and serious adverse events were similar between groups, 9% versus 8.9% [3]. A small Guillain-Barré signal exists, roughly 3 excess cases per million doses within 42 days [2]. The 2026 VAERS analysis is voluntary reporting with no dose denominator, so it cannot give you a real rate [1].

OutcomeShingrixPlacebo
Shingles, age 70+ (ZOE-70)0.9 per 1,000 person-years9.2 per 1,000 [3]
Postherpetic neuralgia (pooled)0.1 per 1,0000.9 per 1,000 [3]
Injection-site pain79.1%11.2% [3]
Serious adverse events9%8.9% [3]

The aortic graft is the open question. Shingles itself raises short-term stroke and heart attack risk in older adults [5], and a graft is a vulnerable surface when inflammation and clotting spike. That is a plausible reason to vaccinate, not proof the vaccine protects the graft. No record here studied graft patients.

My call: worth taking, because the shingles benefit is large and well-measured and the short-term risk is mostly a sore arm. Confidence: moderate on benefit, low on any graft-specific protection.

Keep digging

Sources used 5

  1. Safety profile of herpes zoster vaccines in the United States: a descriptive and disproportionality analysis of adverse events reported to the vaccine adverse event reporting system (VAERS), 2017–2024 Frontiers in Medicine (2026) primary study Strong

    In 69,822 US VAERS reports (2017-2024), herpes zoster vaccine adverse-event reporting was dominated by transient reactogenicity and injection-site reactions, with serious reports uncommon overall (6.6%) and for Shingrix (2.9%) but more frequent for Zostavax (27.6%), largely driv…

    DOI: 10.3389/fmed.2026.1920596
  2. Prevention of Herpes Zoster: A Focus on the Effectiveness and Safety of Herpes Zoster Vaccines Viruses (2022) narrative review Strong

    This narrative review finds real-world vaccine effectiveness of about 46% for live zoster vaccine and about 85% for recombinant zoster vaccine, with mostly local reactions and a small Guillain-Barré syndrome signal to monitor.

    DOI: 10.3390/v14122667
  3. Zoster Vaccine Recombinant, Adjuvanted Hospital Pharmacy (2018) narrative review Strong

    In a narrative review of clinical trial data, adjuvanted recombinant zoster vaccine (Shingrix) showed high efficacy against herpes zoster and postherpetic neuralgia in adults 50 years and older, with mainly transient local and systemic reactions.

    DOI: 10.1177/0018578718767103
  4. Evaluating the Immunogenicity, Efficacy, and Effectiveness of Recombinant Zoster Vaccine for Global Public Health Policy Vaccines (2025) Thin

    RZV is highly effective against herpes zoster and its complications, with protection lasting at least 10 years across age groups and in immunocompromised populations, but policy decisions require additional considerations such as cost-effectiveness and disease burden data.

    DOI: 10.3390/vaccines13030250
  5. Risk of Stroke and Myocardial Infarction After Herpes Zoster in Older Adults in a US Community Population Mayo Clinic Proceedings (2016) Thin

    A US population–based retrospective cohort study in older adults shows herpes zoster is linked to a short-term (within 3 months) increased risk of stroke, with no sustained long-term risk for stroke or myocardial infarction after adjusting for multiple comorbidities, suggesting …

    DOI: 10.1016/j.mayocp.2015.09.015

Your question next

What do you want to know?

No question is too uncomfortable for the evidence. Bring yours.

Ask your question →